| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Y A Hosokawa, H Hosokawa, C Chen, J L Leah. Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37). The Journal of clinical investigation. vol 97. issue 1. 1996-02-16. PMID:8550831. |
to determine if glucose potentiation of nonglucose secretagogues is impaired, insulin responses to 10(-9) m glucagonlike peptide-1 (glp-1) (7-37) were measured at 2.8, 8.3, and 16.7 mm glucose with the in vitro perfused pancreas in rats 4-6 wk after 90% pancreatectomy (px) and sham-operated controls. |
1996-02-16 |
2023-08-12 |
rat |
| Y A Hosokawa, H Hosokawa, C Chen, J L Leah. Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37). The Journal of clinical investigation. vol 97. issue 1. 1996-02-16. PMID:8550831. |
in the controls, insulin output to glp-1 was > 100-fold greater at 16.7 mm glucose versus 2.8 mm glucose. |
1996-02-16 |
2023-08-12 |
rat |
| Y A Hosokawa, H Hosokawa, C Chen, J L Leah. Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37). The Journal of clinical investigation. vol 97. issue 1. 1996-02-16. PMID:8550831. |
in control rats, fasting suppressed insulin release to high glucose (by 90%) and to glp-1 (by 60%) without changing the pancreatic insulin content. |
1996-02-16 |
2023-08-12 |
rat |
| Y A Hosokawa, H Hosokawa, C Chen, J L Leah. Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37). The Journal of clinical investigation. vol 97. issue 1. 1996-02-16. PMID:8550831. |
in contrast, in px the insulin response to glp-1 tripled in association with a threefold increase of the insulin content, both now being twice normal when stratified for the fractional beta-cell mass. |
1996-02-16 |
2023-08-12 |
rat |
| J Schirra, M Katschinski, C Weidmann, T Schäfer, U Wank, R Arnold, B Gök. Gastric emptying and release of incretin hormones after glucose ingestion in humans. The Journal of clinical investigation. vol 97. issue 1. 1996-02-16. PMID:8550855. |
this study investigated in eight healthy male volunteers (a) the gastric emptying pattern of 50 and 100 grams of glucose; (b) its relation to the phase of interdigestive motility (phase i or ii) existing when glucose was ingested; and (c) the interplay between gastric emptying or duodenal perfusion of glucose (1.1 and 2.2 kcal/min; identical total glucose loads as orally given) and release of glucose-dependent insulinotropic peptide (gip), glucagon-like peptide-1(7-36)amide (glp-1), c-peptide, insulin, and plasma glucose. |
1996-02-16 |
2023-08-12 |
human |
| J Schirra, M Katschinski, C Weidmann, T Schäfer, U Wank, R Arnold, B Gök. Gastric emptying and release of incretin hormones after glucose ingestion in humans. The Journal of clinical investigation. vol 97. issue 1. 1996-02-16. PMID:8550855. |
oral administration of glucose yielded higher glp-1 and insulin releases but an equal gip release compared with the isocaloric duodenal perfusion. |
1996-02-16 |
2023-08-12 |
human |
| B Göke, H Fuder, G Wieckhorst, U Theiss, E Stridde, T Littke, P Kleist, R Arnold, P W Lücke. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. vol 56. issue 6. 1996-02-06. PMID:8536820. |
blood was drawn at regular intervals up to 180 min after a standardized breakfast to analyze the levels of glucose, insulin, c peptide, gastric inhibitory polypeptide, and glucagon-like peptide 1 (glp-1). |
1996-02-06 |
2023-08-12 |
human |
| G Crepaldi, S Del Prat. What therapy do our NIDDM patients need? Insulin releasers. Diabetes research and clinical practice. vol 28 Suppl. 1996-02-01. PMID:8529509. |
infusion of glucagon-like peptide 1 (glp-1) in niddm patients improves glucose tolerance through enhancement of acute release of insulin, suppression of glucagon secretion, and improvement of peripheral glucose utilization. |
1996-02-01 |
2023-08-12 |
Not clear |
| T Otonkoski, A Haye. Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530635. |
we have now tested whether glp-1 can induce glucose-responsive insulin release in human fetal islet-like cell clusters (iccs). |
1996-01-31 |
2023-08-12 |
human |
| T Otonkoski, A Haye. Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530635. |
in perifusion, the fetal iccs responded with only minimal insulin release to 16.7 mmol/l glucose or 10 nmol/l glp-1 combined with 1.67 mmol/l glucose. |
1996-01-31 |
2023-08-12 |
human |
| T Otonkoski, A Haye. Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530635. |
however, in the presence of glp-1, the insulin response to glucose was markedly potentiated and appeared in a biphasic manner (10-fold first phase and 3-fold second phase). |
1996-01-31 |
2023-08-12 |
human |
| T Otonkoski, A Haye. Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530635. |
in static incubations, the relative insulin release responses to 16.7 mmol/l glucose plus 10 nmol/l glp-1 were equal in the fetal and adult cells. |
1996-01-31 |
2023-08-12 |
human |
| T Otonkoski, A Haye. Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530635. |
our studies indicate that the glucoincretin hormone glp-1 is able to constitute biphasic insulin release in the immature beta-cell, possibly as the result of camp-mediated priming of the glucose sensor mechanism. |
1996-01-31 |
2023-08-12 |
human |
| J Pá. [Factors with insulin-like effects: IGF-I and GLP-1]. Vnitrni lekarstvi. vol 41. issue 9. 1995-12-26. PMID:7483355. |
glp-1, the use of which would be useful in type 2 diabetics as it stimulates insulin secretion, is not used so far in therapy because hitherto prepared preparations have a very short period of a effectiveness. |
1995-12-26 |
2023-08-12 |
Not clear |
| B Ahrén, S Lindskog, G van Dijk, A J Scheurink, A B Steffen. Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. Endocrine research. vol 21. issue 3. 1995-12-21. PMID:7588428. |
effects of glp-1 and 2,5-anhydro-d-mannitol on insulin secretion and plasma glucose in mice. |
1995-12-21 |
2023-08-12 |
mouse |
| B Ahrén, S Lindskog, G van Dijk, A J Scheurink, A B Steffen. Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. Endocrine research. vol 21. issue 3. 1995-12-21. PMID:7588428. |
the truncated glucagon-like peptide-1 (glp-1(7-36)amide or glp-1) stimulates insulin secretion, enhances glucose elimination and is of potential interest in diabetes treatment. |
1995-12-21 |
2023-08-12 |
mouse |
| B Ahrén, S Lindskog, G van Dijk, A J Scheurink, A B Steffen. Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. Endocrine research. vol 21. issue 3. 1995-12-21. PMID:7588428. |
at 5 min after injection, glp-1 had increased plasma insulin levels to 693 +/- 68 pmol/l compared with 342 +/- 42 pmol/l in controls (p < 0.01). |
1995-12-21 |
2023-08-12 |
mouse |
| Y Wang, J M Egan, M Raygada, O Nadiv, J Roth, C Montrose-Rafizade. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. vol 136. issue 11. 1995-11-27. PMID:7588224. |
it has been previously demonstrated that the enteric hormone glucagon-like peptide-1 (7-36 amide) (glp-1) has acute effects on glucose-induced insulin secretion by rin 1046-38 cells. |
1995-11-27 |
2023-08-12 |
Not clear |
| Y Wang, J M Egan, M Raygada, O Nadiv, J Roth, C Montrose-Rafizade. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. vol 136. issue 11. 1995-11-27. PMID:7588224. |
in this study, we investigated the effects of extended exposure of rin 1046-38 cells to glp-1 and examine the mechanism by which glp-1 synergizes with glucose in stimulating insulin secretion. |
1995-11-27 |
2023-08-12 |
Not clear |
| Y Wang, J M Egan, M Raygada, O Nadiv, J Roth, C Montrose-Rafizade. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. vol 136. issue 11. 1995-11-27. PMID:7588224. |
compared with cells cultured with glucose alone, incubation of cells with glucose plus 1 or 10 nm glp-1 for 12 or 24 h significantly increased insulin release by about 3-fold, intracellular insulin content by 1.5-fold, and insulin messenger rna (mrna) by almost 2.5-fold. |
1995-11-27 |
2023-08-12 |
Not clear |